# Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

> **NCT07630961** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 66 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Non-small Cell Lung Cancer (NSCLC)
- HR+/HER2- Ductal Breast Cancer (BC)
- HR+/HER2- Lobular Breast Cancer (BC)
- Triple Negative Breast Cancer (TNBC)
- Colorectal Cancer (CRC)
- Soft Tissue Sarcoma (STS)

## Interventions

- **DRUG:** 68Ga-DFC413
- **DRUG:** 68Ga-NNS309

## Key facts

- **NCT ID:** NCT07630961
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-23
- **Primary completion:** 2028-01-16
- **Final completion:** 2028-01-16
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07630961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07630961, "Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07630961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*